血清miR-122影响肝细胞癌的最新研究进展

承德医学院学报 ›› 2026, Vol. 43 ›› Issue (2): 146-151.

血清miR-122影响肝细胞癌的最新研究进展

陈骑东¹, 韩红彪^2,3, 秦锡亮^1,2, 周帅², 朱超², 刘会春², 金浩^2,*

1.蚌埠医科大学研究生院,安徽蚌埠 233000;
2.安徽省第二人民医院普外四病区肝胆胰外科,安徽合肥 230041;
3.安徽医科大学研究生院,安徽合肥 230000

收稿日期:2025-06-09 出版日期:2026-04-10 发布日期:2026-05-07
通讯作者: *金浩（1981—）,男,博士,主任医师;研究方向：肝胆胰外科;E-mail:jinhaogandan@163.com。
作者简介:陈骑东（1996—）,男,硕士研究生在读;研究方向：普通外科学。
基金资助:
安徽省高校自然科学研究重大项目（2023AH040392）; 安徽省高校自然科学研究重点项目（2023AH053366,2023AH053384）; 蚌埠医科大学研究生科研创新项目（Byycx23124）

Received:2025-06-09 Online:2026-04-10 Published:2026-05-07

摘要/Abstract

中图分类号:

R735.7

陈骑东, 韩红彪, 秦锡亮, 周帅, 朱超, 刘会春, 金浩. 血清miR-122影响肝细胞癌的最新研究进展[J]. 承德医学院学报, 2026, 43(2): 146-151.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://tougao.cdmc.edu.cn/CN/

https://tougao.cdmc.edu.cn/CN/Y2026/V43/I2/146

[1] Vogel A, Meyer T, Sapisochin G, et al.Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362.
[2] Wang X, Teh CSC, Ishizawa T, et al.Consensus Guidelines for the Use of Fluorescence Imaging in Hepatobiliary Surgery[J]. Ann Surg, 2021, 274(1): 97-106.
[3] Wang X, He Y, Mackowiak B, et al.MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases[J]. Gut, 2020, 70(4): 784-795.
[4] Yuan D, Chen Y, Li X, et al.Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis[J]. Int J Biol Sci, 2021, 17(1): 220-235.
[5] Al-Gazally ME, Khan R, Imran M, et al.The role and mechanism of action of microRNA-122 in cancer: Focusing on the liver[J]. Int Immunopharmacol, 2023, 123: 110713.
[6] Huynh KN, Rao S, Roth B, et al.Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma[J]. Cancers (Basel), 2023, 15(10): 2738.
[7] Yang X, Yao B, Niu Y, et al.Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122-5p/CTNND2 axis[J]. Biochem Biophys Res Commun, 2019, 518(2): 239-245.
[8] Hossain MM, Mishra AK, Yadav AK, et al.MicroRNA-122 regulates inflammatory and autophagic proteins by downregulating pyruvate kinase M2 in non-alcoholic fatty liver disease[J]. Mol Cell Biochem, 2024, 480(5): 1-12.
[9] Wang X, Zhang P, Deng K.MYC Promotes LDHA Expression through MicroRNA-122-5p to Potentiate Glycolysis in Hepatocellular Carcinoma[J]. Anal Cell Pathol (Amst), 2022, 2022: 1435173.
[10] Wang P, Yang X, Liu D, et al. Construction of a Competing Endogenous RNA Network to Analyse Glucose-6-Phosphate Dehydrogenase Dysregulation in Hepatocellular Carcinoma[J]. Biosci Rep, 2022, 42(6): BSR20220674.
[11] Caviglia GP, Casalone E, Rosso C, et al.Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease[J]. Aliment Pharmacol Ther, 2025, 62(1): 22-32.
[12] Chai C, Rivkin M, Berkovits L, et al.Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues[J]. Gastroenterology, 2017, 153(5): 1404-1415.
[13] Sengupta D, Cassel T, Teng KY, et al.Regulation of hepatic glutamine metabolism by miR-122[J]. Mol Metab, 2020, 34: 174-186.
[14] Quirico L, Orso F, Cucinelli S, et al.miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression[J]. Cell Mol Life Sci, 2022, 79(4): 216.
[15] Yang QS, Zhang M, Ma CS, et al.Analysis of risk factors for bile leakage after laparoscopic exploration and primary suture of common bile duct[J]. World J Gastrointest Surg, 2025, 17(3): 102190.
[16] Xu Y, Huang J, Ma L, et al.MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J]. Cancer Lett, 2016, 371(2): 171-181.
[17] Turato C, Fornari F, Pollutri D, et al.MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma[J]. J Clin Med, 2019, 8(2): 171.
[18] Dai J, Hao Y, Chen X, et al.miR-122/SENP1 axis confers stemness and chemoresistance to liver cancer through Wnt/β-catenin signaling[J]. Oncol Lett, 2023, 26(3): 390.
[19] Jao TM, Fang WH, Ciou SC, et al.PCDH10 exerts tumor-suppressor functions through modulation of EGFR/AKT axis in colorectal cancer[J]. Cancer Lett, 2021, 499: 290-300.
[20] Wang W, Liu WB, Huang DB, et al.Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma[J]. Am J Cancer Res, 2016, 6(8): 1681-1694.
[21] Bai Y, Xiong Y, Zhang YY, et al.Tangeretin Synergizes with 5-Fluorouracil to Induce Autophagy through MicroRNA-21 in Colorectal Cancer Cells[J]. Am J Chin Med, 2022, 50(6): 1681-1701.
[22] Wang D, Sun X, Wei Y, et al.Nuclear miR-122 directly regulates the biogenesis of cell survival oncomiR miR-21 at the posttranscriptional level[J]. Nucleic Acids Res, 2018, 46(4): 2012-2029.
[23] Cuevas D, Amigo R, Agurto A, et al.The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression[J]. Biomedicines, 2024, 12(8): 1915.
[24] Riccioni V, Trionfetti F, Montaldo C, et al.SYNCRIP Modulates the Epithelial-Mesenchymal Transition in Hepatocytes and HCC Cells[J]. Int J Mol Sci, 2022, 23(2): 913.
[25] Chun KH.Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma[J]. Pharmaceutics, 2022, 14(7): 1380.
[26] Wang SC, Lin XL, Li J, et al.MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA[J]. PLoS One, 2014, 9(7): e101330.
[27] Wan Y, Li M, Huang P.LINC01296 promotes proliferation, migration, and invasion of HCC cells by targeting miR-122-5P and modulating EMT activity[J]. Onco Targets Ther, 2019, 12: 2193-2203.
[28] Yuan S, Si W, Zhuang K, et al.LncRNA UCID Promotes Hepatocellular Carcinoma Metastasis via Stabilization of Snail[J]. Onco Targets Ther, 2021, 14: 725-736.
[29] Liang Y, Zhang D, Zheng T, et al.lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2[J]. Oncogenesis, 2020, 9(5): 54.
[30] Elfert AY, Salem A, Abdelhamid AM, et al.Implication of miR-122, miR-483, and miR-335 Expression Levels as Potential Signatures in HCV-Related Hepatocellular Carcinoma (HCC) in Egyptian Patients[J]. Front Mol Biosci, 2022, 9: 864839.
[31] Deng P, Li M, Wu Y.The Predictive Efficacy of Serum Exosomal microRNA-122 and microRNA-148a for Hepatocellular Carcinoma Based on Smart Healthcare[J]. J Healthc Eng, 2022, 2022: 5914541.
[32] Zhan G, Jiang H, Yang R, et al.miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis[J]. Am J Transl Res, 2021, 13(6): 6731-6737.
[33] Wischhusen JC, Chowdhury SM, Lee T, et al.Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo[J]. J Control Release, 2020, 321: 272-284.
[34] Zavadil J, Juráček J, Čechová B, et al.Dynamic Changes in Circulating MicroRNA Levels in Liver Cancer Patients Undergoing Thermal Ablation and Transarterial Chemoembolization[J]. Klin Onkol, 2019, 32(Supplementum1): 164-166.
[35] Colaianni F, Zelli V, Compagnoni C, et al.Role of Circulating microRNAs in Liver Disease and HCC: Focus on miR-122[J]. Genes (Basel), 2024, 15(10): 1313.
[36] Zhang Y, Li Y, Jiang W, et al.The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset[J]. Medicine (Baltimore), 2019, 98(13): e14810.
[37] Ha SY, Yu JI, Choi C, et al.Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 14738.

血清miR-122影响肝细胞癌的最新研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	金雯, 李群, 王波, 周健坤, 张俊, 曹立宇. LncRNA MITA1靶向miR-30b-3p对肝细胞癌细胞生物学活性的影响[J]. 承德医学院学报, 2026, 43(1): 1-6.
[2]	冯伟涛, 杨鹏达, 白春英, 段静璇, 李远洋, 殷涛. miRNA调控肝细胞癌上皮间充质转化的研究进展[J]. 承德医学院学报, 2025, 42(1): 64-68.
[3]	杨世瑜, 肖雨, 高思齐, 李继安, 邱昌龙, 储金秀. 糖尿病脑病发病机制的研究进展[J]. 承德医学院学报, 2024, 41(5): 417-421.
[4]	赵雯, 赵杨, 赵宇阳, 刘赛璇, 申兴斌. STAT5在结直肠癌中的研究进展[J]. 承德医学院学报, 2024, 41(5): 421-425.
[5]	彭克楠, 宁静源, 孙克然, 范小晴, 宗彦红, 唐志鹏, 帖彦清. 肝癌中m7G甲基化相关lncRNAs预后模型和动态列线图的开发[J]. 承德医学院学报, 2023, 40(5): 366-371.
[6]	吴涛, 杨柳, 聂山茂, 张杨, 张鑫. 长链非编码RNA SNHG16通过miR-141-3p/FOXJ3通路调控肝细胞癌的增殖[J]. 承德医学院学报, 2022, 39(4): 271-276.
[7]	王波, 金雯, 周健坤, 陈良, 曹立宇. Lnc RNA CUDR敲低对肝癌侵袭、增殖和凋亡的影响[J]. 承德医学院学报, 2022, 39(3): 196-200.
[8]	祝盼盼, 商亚珍. MAPK信号通路介导细胞凋亡的研究进展[J]. 承德医学院学报, 2021, 38(3): 243-245.
[9]	徐陈, 韩杰. 上尿路结石微创治疗新进展[J]. 承德医学院学报, 2021, 38(2): 149-151.
[10]	邱颖, 汪家龙. 急性粒细胞性白血病治疗药物研究进展[J]. 承德医学院学报, 2020, 37(6): 516-520.
[11]	邢鑫, 黄发贵, 李建国. 急性危重肾衰竭患者经血液净化治疗的研究进展[J]. 承德医学院学报, 2020, 37(5): 419-422.
[12]	王欢欢, 杨圣. 腰椎管狭窄症微创治疗的研究进展[J]. 承德医学院学报, 2020, 37(2): 166-168.
[13]	徐辉, 许长理. 不同途径前列腺穿刺活检的研究进展^*[J]. 承德医学院学报, 2018, 35(4): 330-333.
[14]	孙一婵, 李东哲, 王丹丹, 宋妤轩, 宋成军, 陈志宏. 2型糖尿病与消化系统恶性肿瘤的关系研究进展^*[J]. 承德医学院学报, 2018, 35(3): 239-241.
[15]	李东哲, 刘美晓, 宋成军, 陈志宏. PI3K/Akt信号通路及PTEN与糖尿病肾病研究进展[J]. 承德医学院学报, 2018, 35(1): 69-73.